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31 Dear Editors, 
 
32 Low-molecular-weight heparins (LMWHs) are used for the prevention of venous 
33 thromboembolism (VTE) [1]. Compared to unfractionated heparin (UFH), they offer a 
34 number of advantages, including a simplified dosing schedule, improved adherence  and 
35 decreased  risk  for  heparin-induced  thrombocytopenia  [2,  3].  Severe  chronic  kidney 
36 disease (CKD) represents a high risk for VTE in hospitalised patients (1-3). Clinicians 
37 typically prefer UFH over LMWH for thromboprophylaxis in severe CKD because of 
38 concerns with bioaccumulation and possible increased risk for bleeding [4, 5]. However, 
39 data support the use of tinzaparin in patients with moderately impaired renal function [6, 
40 7]. The aim of this observational study was to assess the severity of accumulation of 
41 tinzaparin when given at prophylactic doses in patients with severe CKD. 
 
 
42 Methods 
 
43 The STRIP study was a prospective observational study at the Maisonneuve- 
44 Rosemont Hospital between February and September 2016. The study protocol was 
45 approved by the local research ethics board and Health Canada, and was registered 
46 with ClinicalTrials.gov (NCT02719418). Informed consent was obtained. Local 
47 thromboprophylaxis guidelines recommend a fixed daily dose of subcutaneous 
48 tinzaparin of 3500 IU, with reduction to 2500 IU for patients with body weight <40 kg or 
49 an increase to 4500 IU for patients with a BMI ≥30 kg/m2. This study included 
50 hospitalized patients>18 years of age, with estimated glomerular filtration rate (eGFR) 
51 ≤30   ml/min/1.73m2,   who   were   prescribed   tinzaparin   for   prophylaxis (nonsurgical 
52 indication). The CKD-EPI formula was used to calculate the eGFR because of its ease of 
53 use and its improved accuracy to evaluate renal function compared to the Cockcroft- 
54 Gault equation [8]. Exclusion criteria were: body mass index (BMI) >50 kg/m2, severe 
55 hepatic impairment (Child-Pugh C), acute kidney injury with mean baseline eGFR > 30 
56 ml/min/1.73 m2, anuria or current renal replacement therapy (ex. hemodialysis), and use 
57 of tinzaparin at a prophylactic dose for ≥72h before recruitment. Patients receiving the 
58 following anticoagulants were also excluded: argatroban or bivalirudin (< 24h), 
59 therapeutic UFH, LMWH or oral factor Xa inhibitors (< 48h), oral direct thrombin 
60 inhibitors, danaparoid, fondaparinux, or anti-vitamin K (< 7 days), prophylactic dose of 
61 LMWH other than tinzaparin (< 48h), prophylactic dose of UFH (< 12h). 
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62 The primary outcome was bioaccumulation, defined as a peak anti-Xa activity 
63 level >20% higher  on day 5  as  compared with day 2  [6,  9]. Secondary outcomes were 
64 bioaccumulation between days 2 and 8 and a trough anti-Xa level >0.40 IU/ml on day 5, 
65 which is indicative of excessive anticoagulation [10]. Peak anti-Xa levels were measured 
66 4h after dosing on days 2, 5 and 8 and trough levels were obtained within 4h of the next 
67 dose on day 5. The medical staff and the project team were blinded to anti-Xa levels. 
68 Plasma anti-Xa activity (IU/ml) was determined with the STA®-Liquid Anti-Xa 
69 chromogenic assay (Stago, France; limit of quantification (LOQ), 0.1 IU/ml). A 
70 replacement approach (LOQ/√2) was used when anti-Xa levels were below the LOQ 
71 [11]. Statistical analysis was carried out with XlStat version 19. With a paired one-tailed t 
72 test, an alpha error of 0.05, a power of 90%, a minimum of 25 participants were required 
73 to detect an increase ≥ 20 % in anti-Xa activity between sampling on day 2 or 3 and day 
74 5. The one-tailed Wilcoxon rank sum test was used for matched-paired samples of peak 
75 anti-Xa values on days 2 and 5 or 8. P-value > 0.05 was considered statistically 
76 significant. 
 
 
77 Results 
 
78 A total of 39 patients were assessed for eligibility and 11 refused to participate. 
79 Of the 28 patients enrolled, 14 completed the study (3 were discharged from the hospital 
80 before day 5, 1 withdrew consent, 1 was switched to UFH, 3 had their treatment 
81 interrupted for a medical intervention, 2 missed samples and 4 had their eGFR rise 
82 above 30 ml/min/1.73m2) (see supplementary Fig 1). Baseline characteristics are shown 
83 in Table 1. Most patients received a dose of 3500 IU daily (70%), whereas patients with 
84 a BMI ≥30 kg/m2 were given 4500 IU daily, as per local guidelines. The median eGFR 
85 (IQR) was stable over the course of the study: 16 (12-25) (baseline), 18 (14-21) (day 5) 
90 and 16 (13-22) (day 8) ml/min/1.73m2. 
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95 Table 1. Baseline characteristics of patients 
96 
 
Variables1,2 Recruited 
 
 
(n = 28) 
Completed a 5 
days course of 
treatment 
(n = 14) 
Completed a 8 
days course of 
treatment 
(n = 10) 
Age in years 73 (69-85) 73 (67-86) 72 (66-84) 
Male 17 (61 %) 9 (64 %) 6 (60%) 
Caucasian 26 (93 %) 13 (93 %) 9 (90%) 
African American 2 (7 %) 1 (7 %) 1 (10%) 
Weight in kg 79 (66-91) 77 (63-91) 77 (66-86) 
BMI in kg/m2 30 (25-33) 28 (23-32) 28 (22-32) 
eGFR 3 at baseline 20 (16-24) 16 (12-25) 19 (13-24) 
Patients with eGFR 
at baseline ≤ 20 
ml/min/1.73m2 
15 (54 %) 9 (64.3 %) 6 (60%) 
Dose of tinzaparin in IU/kg 44 (42-54) 48 (42-56) 48 (44-55) 
Patients with dose of 3500 
IU 
19 (68 %) 10 (71 %) 7 (70%) 
1 Continuous variables are given as median (interquartile range - IQR) 
 
2 Discrete variables are given as counts (%) 
 
3 eGFR = estimated glomerular filtration rate using CKD-EPI [8] 
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99 Median peak anti-Xa levels (range) measured at 4h on day 2 were 0.07 (0-0.24) 
100 IU/ml, 0.11 (0.07–0.25) IU/mL on day 5 and 0.09 (0.07–0.31) IU/ml on day 8. There was 
101 no statistically significant increase in peak anti-Xa levels over time between day 2 and 
102 day 5 (Figure 1). Ranges of peak anti-Xa levels were comparable to surgical patients 
103 with normal renal function receiving a 3500 IU dose of tinzaparin [12]. The difference 
104 between day 2 and day 8 was to the limit of statistical significance. Nevertheless, all anti- 
105 Xa values measured at peak or trough remained below 0.4 IU/ml (trough anti-Xa levels 
106 were undetectable), thus suggesting an absence of disproportionate anticoagulation. No 
107 patient experienced thrombotic complications or major bleeding events. One patient 
108 received two units of red blood cells on day 5 for symptomatic anemia not related to 
109 bleeding and anticoagulation was maintained. 
 
 
110 Discussion 
 
111 Our study shows that short-term tinzaparin in patients severe CKD is not 
112 associated with excessive anticoagulation, with peak anti-Xa levels below the 
113 therapeutic range and undetectable trough anti-Xa levels. Our findings are consistent 
114 with the study of Mahé et al. where a short course of fixed-dose prophylactic tinzaparin 
115 did not show clinically significant accumulation (peak, trough or area under the curve) in 
116 elderly patients mainly with moderate renal impairment [6]. Similarly, a low dependence 
117 of peaks anti-Xa ratio on baseline renal function was reported in elderly patients with 
118 renal impairment receiving therapeutic doses of tinzaparin [13]. 
 
119 Strengths of our study include prophylactic tinzaparin given exclusively to 
120 patients with severe CKD and median eGFR <20 ml/min/1.73m2 over the whole course 
121 of the trial (as opposed to a majority of patients with moderate CKD in other studies), 
122 systematic assessment of bioaccumulation of tinzaparin using trough and peak anti-Xa 
123 levels and blinding of the clinical staff for the duration of the study. 
 
124 Limitations of this observational single center study were the use of anti-Xa levels 
125 as a pharmacokinetic biomarker for bleeding risk, overall low anti-Xa blood levels and 
7  
126 most importantly sample size. Although we have enrolled 28 participants, half did not 
127 complete a 5-8-day tinzaparin course. This is reflective of the real-world trajectories of 
128 patients with severe CKD receiving prophylactic tinzaparin on medical wards. With 14 
129 individuals in the final cohort, we had 85% power to detect a 20% difference with a 5% α 
130 error. 
 
131 In summary, although caution should be used with LMWHs in severe CKD, a 
132 short course of tinzaparin for prevention of VTE in this high-risk population appears safe. 
133 It does not support lowering the prophylactic dose in severe CKD. Further clinical studies 
134 to assess the relative thrombotic efficacy versus bleeding risk of low-dose tinzaparin in 
135 this population would benefit from validation in a larger cohort, despite the feasibility 
136 challenge. 
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216 Figures Captions 
217 
218 Figure 1. Dot plot comparing the detectable peak anti-Xa plasma levels of 
219 individual patients on day 2, day 5 and day 8. LOQ = limit of quantification. A 
220 substitution approach (LOQ / √2) was applied when anti-Xa levels were below LOQ. Two 
221 patients had peak anti-Xa on day 3 instead of day 2. For these subjects, all anti-Xa 
222 levels, including day 5 and 8 were below 0.1 IU/ml. Differences between day 2 and day 5 
223 or day 8 were not considered clinically significant (p = 0.22 and p=0.05, one-tailed 
224 Wilcoxon rank sum test on matched pairs). 
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